Replies to post #42061 on Humanigen Inc (fka HGENQ)

[cowtown jay]

We have to assume that Humanigen has a license to use lenz, since Taran bought the IP...or, we just need to see the merger or business combination between Taran and Humanigen. I think that Humanigen has every intention to use lenz for covid, or Durrant would have simply bought out Humanigen.

[cowtown jay]

In my initial reply to your post, I failed to acknowledge the first clause in your question. The answer, despite my earlier language in an unrelated post, is that, yes, all is well with me.

However, someone I care about is having some health issues, and I wanted her to see the videos in a couple of my posts. She had told me that she has had some boosters, following a Pfizer vaccine. I have never had a post rejected on this site, AND blocked on X. But, there's a first time for everything. So I had to email the videos to her, and hope that she can open the videos from her email, or that she finds those videos in other of my postings here.

You also expressed some question about Humanigen's right to use lenz. And I see others here also concerned about our future.

For years, I have talked about the "script" written in our company's history. In 2015, as now, the company was forced into a CH11 bankruptcy, just as we were again forced to do. And too many shareholders are failing to continue looking to our past, to project our future. This wasn't The End of the company in 2015, and it isn't The End of the company now, either.

Shareholders need to realize that Humanigen remains on track toward accomplishing their goals. If there has been a change, I think we may see management rely more on foreign regulatory approval. Certainly, we are seeing the British parliament address issues such as excess deaths from mRNA vaccines. This has got to force the MHRA to abandon the status quo, and to consider granting approval of lenz to treat covid.

Other treatments could even capitalize on plant-based alternatives to controlling cytokine release syndrome.

https://www.nasdaq.com/press-release/gb-sciences-targets-covid-19-treatment-as-omicron-variant-arrives-2021-12-06

I think we may be in an ETF with them (but don't ask me to explain that). All I could do was to buy a small number shares in the company.

Finally, to me, there was an unknown distinction between SAR-S CoV-2 coronavirus in nucleocapsid proteins, caused by the virus, versus covid spike proteins caused by the mRNA vaccines. I really hope that a study has been done focused on the reduction of nucleocapsid covid proteins after administering lenz.